Internal Medicine, Hematology & Oncology · Bethesda, MD
NPI
1467544312
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
6410 Rockledge Dr Ste 660
Bethesda, MD, 20817
Phone (301) 571-0019
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.5M
219,760 services
Medicare patients, 2024
782
Average age 76
Drug cost, 2024
$5.4M
1,640 prescriptions
Company payments, 2025
$1,863
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chitra Rajagopal was code J1439 (injection, ferric carboxymaltose, 1 mg), 87,750 times for 46 patients. In total Chitra Rajagopal billed 219,760 services in 105 codes, and Medicare paid $2.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 87,750 | 46 | $0.87 | $76K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 18,481 | 70 | $5.77 | $107K |
| J1756 Injection, iron sucrose, 1 mg | Office | 14,400 | 22 | $0.18 | $2,556 |
| J0897 Injection, denosumab, 1 mg | Office | 9,180 | 52 | $20.30 | $186K |
| 85025 Blood Count | Office | 3,004 | 741 | $7.61 | $23K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,640 | 26 | $5.72 | $15K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2,601 | 11 | $35.50 | $92K |
| 36415 Venipuncture Blood Collection | Office | 2,322 | 607 | $8.65 | $20K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,374 | 29 | $0.09 | $123 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,050 | 14 | $0.25 | $262 |
| 96372 Injection Administration | Office | 1,044 | 162 | $13.04 | $14K |
| 99214 Office E&M - Established | Office | 590 | 341 | $118.67 | $70K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 436 | 11 | $0.23 | $99.41 |
| 96367 Intravenous Infusion, Hydration | Office | 315 | 42 | $27.19 | $8,564 |
| 96365 Intravenous Infusion, Hydration | Office | 307 | 90 | $59.80 | $18K |
By year: 2022 $3.5M for 229,443 services; 2023 $2.4M for 212,073 services; 2024 $2.5M for 219,760 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,004 | 741 | $7.61 | $23K |
| 36415 Venipuncture Blood Collection | 2,322 | 607 | $8.65 | $20K |
Medicare prescription drug claims, 2024
In 2024, the drug Chitra Rajagopal prescribed most often to Medicare patients was Anastrozole, with 298 prescriptions and refills. In total Chitra Rajagopal wrote 1,640 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 298 | 833 | 90 | $8,377 |
| Eliquis Apixaban | 142 | 318 | 41 | $181K |
| Xarelto Rivaroxaban | 87 | 226 | 28 | $123K |
| Letrozole Generic | 82 | 235 | 25 | $2,609 |
| Lenalidomide Generic | 44 | 44 | Under 11 | $649K |
| Brukinsa Zanubrutinib | 44 | 44 | Under 11 | $675K |
| Warfarin Sodium Generic | 39 | 114 | 14 | $347 |
| Lorazepam Generic | 37 | 87 | 11 | $391 |
| Dexamethasone Generic | 37 | 51 | 13 | $679 |
| Imbruvica Ibrutinib | 35 | 35 | Under 11 | $589K |
| Jakafi Ruxolitinib Phosphate | 34 | 42 | Under 11 | $515K |
| Exemestane Generic | 30 | 86 | 11 | $9,852 |
| Ibrance Palbociclib | 27 | 27 | Under 11 | $431K |
| Dapsone Generic | 25 | 72 | Under 11 | $1,166 |
| Revlimid Lenalidomide | 24 | 24 | Under 11 | $521K |
Brand drugs: - claims; generic drugs: 1,127 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chitra Rajagopal $1,863 ($1,863 in general payments such as food, travel and fees) from 22 companies. The largest payer was Avyxa Pharma, LLC with $1,000.
| Company | Payments | Amount |
|---|---|---|
| Avyxa Pharma, LLC | 1 | $1,000 |
| Genzyme Corporation SNY | 4 | $101 |
| GlaxoSmithKline, LLC. GSK | 3 | $87.85 |
| Merck Sharp & Dohme LLC MRK | 2 | $65.49 |
| Abbvie Inc. ABBV | 2 | $63.09 |
| Karyopharm Therapeutics Inc. KPTI | 2 | $61.68 |
| Pfizer Inc. PFE | 2 | $60.59 |
| Daiichi Sankyo Inc. 4568.T | 2 | $55.99 |
| Array Biopharma Inc PFE | 2 | $42.61 |
| Astellas Pharma US Inc 4503.T | 1 | $32.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.